Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/8632Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papathanasiou, A. I. | en |
| dc.contributor.author | Goudevenos, J. A. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.date.accessioned | 2015-11-24T16:43:00Z | - |
| dc.date.available | 2015-11-24T16:43:00Z | - |
| dc.identifier.issn | 1699-3993 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/8632 | - |
| dc.rights | Default Licence | - |
| dc.subject | platelet glycoprotein iib/iiia | en |
| dc.subject | acute coronary syndromes | en |
| dc.subject | acute myocardial-infarction | en |
| dc.subject | st-segment elevation | en |
| dc.subject | peripheral arterial-disease | en |
| dc.subject | placebo-controlled trial | en |
| dc.subject | low-dose aspirin | en |
| dc.subject | american-heart-association | en |
| dc.subject | transient ischemic attack | en |
| dc.subject | high-risk patients | en |
| dc.title | Acute and long-term antiplatelet therapy | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | DOI 10.1358/dot.2008.44.5.1215717 | - |
| heal.identifier.secondary | <Go to ISI>://000256918300003 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha(IIb)beta(3)) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved. | en |
| heal.journalName | Drugs of Today | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
